According to the latest estimates, the global prevalence of Alzheimer's disease will quadruple to 106 million by 2050. To date there is no single test or biomarker that can predict whether a particular person will develop the affliction. Thus, there is a critical need for effective diagnostic tools to help in the early diagnosis of this debilitating disease.

PredictAD is an EU funded research project aiming at developing a standardised and objective solution that would enable an earlier diagnosis of Alzheimer’s disease, improved monitoring of treatment efficacy and enhanced cost-effectiveness of diagnostic protocols. The development of novel therapeutics relying on novel biomarkers and diagnostics offers hope to individuals and to society. With a consortium of top-level European research and industrial partners, PredictAD takes the opportunity to warrant that hope as well as strengthen the EU’s leadership on the market in this field.

PredictAD consortium members are VTT Technical Research Centre of Finland, GE Healthcare (UK), Nexstim Ltd. (Finland), University of Kuopio (Finland), Imperial College of London (UK), Karolinska Institutet (Sweden), University of Milan (Italy) and Copenhagen University Hospital, Rigshospitalet (Denmark). This project is partially funded under the 7th Framework Programme by the European Commission.